New immune therapy tested for aggressive thyroid cancers
NCT ID NCT05453799
Summary
This study is testing whether an immunotherapy drug called vudalimab can shrink tumors in patients with advanced anaplastic thyroid cancer or Hurthle cell thyroid cancer. The drug is designed to help the patient's own immune system attack the cancer. The trial will enroll about 54 adults whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.